karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Company profile
Ticker
KPTI
Exchange
Website
CEO
Michael Kauffman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Karyopharm Securities Corp. • Karyopharm Europe GmbH • Karyopharm Israel Ltd. ...
IRS number
263931704
KPTI stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
SC TO-C
Information about tender offer
8 Apr 24
PRE 14A
Preliminary proxy
8 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
29 Feb 24
8-K
Other Events
20 Feb 24
8-K
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
8 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Dec 23
Transcripts
KPTI
Earnings call transcript
2023 Q4
29 Feb 24
KPTI
Earnings call transcript
2023 Q3
2 Nov 23
KPTI
Earnings call transcript
2023 Q2
2 Aug 23
KPTI
Earnings call transcript
2023 Q2
2 Aug 23
KPTI
Earnings call transcript
2023 Q1
4 May 23
KPTI
Earnings call transcript
2023 Q1
4 May 23
KPTI
Earnings call transcript
2022 Q4
15 Feb 23
KPTI
Earnings call transcript
2022 Q3
4 Nov 22
KPTI
Earnings call transcript
2022 Q2
4 Aug 22
KPTI
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 44.58 mm | 44.58 mm | 44.58 mm | 44.58 mm | 44.58 mm | 44.58 mm |
Cash burn (monthly) | 12.42 mm | 2.37 mm | 11.50 mm | 11.63 mm | 9.84 mm | 8.42 mm |
Cash used (since last report) | 90.47 mm | 17.28 mm | 83.74 mm | 84.66 mm | 71.69 mm | 61.29 mm |
Cash remaining | -45.89 mm | 27.30 mm | -39.16 mm | -40.08 mm | -27.11 mm | -16.70 mm |
Runway (months of cash) | -3.7 | 11.5 | -3.4 | -3.4 | -2.8 | -2.0 |
Institutional ownership, Q4 2023
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 4 |
Closed positions | 110 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 178.14 mm |
Total shares | 279.30 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Exchange Traded Concepts | 115.86 k | $100.22 mm |
SG Americas Securities | 73.43 k | $64.00 k |
Bleakley Financial | 37.94 k | $32.82 mm |
Redwood Wealth Management | 29.73 k | $25.72 mm |
Diversified Trust | 18.58 k | $16.07 mm |
Founders Capital Management | 2.00 k | $1.73 mm |
AdvisorNet Financial | 700.00 | $606.00 k |
Bruce G. Allen Investments | 507.00 | $439.00 k |
Allworth Financial | 500.00 | $433.00 k |
West Branch Capital | 48.00 | $42.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 May 24 | Richard A. Paulson | Common Stock | Sell | Dispose S | No | No | 1.13 | 3,576 | 4.04 k | 1,153,697 |
22 Apr 24 | Reshma Rangwala | Common Stock | Sell | Dispose S | No | No | 1.17 | 6,789 | 7.94 k | 342,931 |
4 Apr 24 | Richard A. Paulson | Common Stock | Sell | Dispose S | No | No | 1.29 | 3,563 | 4.60 k | 1,157,273 |
1 Mar 24 | Reshma Rangwala | Common Stock | Sell | Dispose S | No | No | 1.2 | 5,969 | 7.16 k | 349,720 |
1 Mar 24 | Stuart Poulton | Common Stock | Sell | Dispose S | No | No | 1.2 | 6,155 | 7.39 k | 329,511 |
29 Feb 24 | Reshma Rangwala | Common Stock | Sell | Dispose S | No | No | 1.17 | 15,667 | 18.33 k | 355,689 |
29 Feb 24 | Stuart Poulton | Common Stock | Sell | Dispose S | No | No | 1.17 | 16,311 | 19.08 k | 335,666 |
News
Karyopharm Announces Presentations In Endometrial Cancer And Myelofibrosis At The 2024 American Society Of Clinical Oncology Annual Meeting
24 Apr 24
Onco360 Selected As The Preferred National Specialty Pharmacy Partner For Karyopharm's Product XPOVIO, A First-In-Class, XPO-1 Inhibitor
13 Mar 24
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8
1 Mar 24
Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
29 Feb 24
Earnings Scheduled For February 29, 2024
29 Feb 24
Press releases
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
2 May 24
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
24 Apr 24
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)
13 Mar 24
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24